Form 8-K - Current report:
SEC Accession No. 0001193125-25-023570
Filing Date
2025-02-10
Accepted
2025-02-10 16:01:16
Documents
15
Period of Report
2025-02-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d886749d8k.htm   iXBRL 8-K 26583
2 EX-3.1 d886749dex31.htm EX-3.1 29071
3 EX-3.2 d886749dex32.htm EX-3.2 120516
  Complete submission text file 0001193125-25-023570.txt   348158

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sion-20250206.xsd EX-101.SCH 2877
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sion-20250206_lab.xml EX-101.LAB 19482
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sion-20250206_pre.xml EX-101.PRE 12171
17 EXTRACTED XBRL INSTANCE DOCUMENT d886749d8k_htm.xml XML 3971
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42504 | Film No.: 25605653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)